{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"196"}],"units":"Participants"}],"title":"Baseline evaluable participants"},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"188"}],"units":"Participants"}],"title":"Post-baseline evaluable participants"}],"denoms":[{"counts":[{"groupId":"OG000","value":"198"}],"units":"Participants"}],"description":"The baseline prevalence and post-baseline incidence of ADAs against atezolizumab.","groups":[{"description":"Participants received intravenous infusions of atezolizumab 1200 milligrams (mg) in combination with carboplatin to achieve an initial target area under the concentration-time curve (AUC) of 5 milligrams per milliliter per minute (mg/mL/min) followed by etoposide 100 milligrams per square meter (mg/m\\^2) on Day 1 of every 21-day cycle during the induction phase (Cycles 1-4). On Days 2 and 3 of every 21-day cycle during the induction phase (Cycles 1-4), etoposide 100 mg/m\\^2 was administered alone. Thereafter, participants received maintenance (Cycle 5 onward) atezolizumab 1200 mg on Day 1 of every 21-day cycle until persistent radiographic PD, symptomatic deterioration, intolerable toxicity, withdrawal of consent, death, or study termination by the Sponsor.","id":"OG000","title":"Atezolizumab + Carboplatin + Etoposide"}],"paramType":"NUMBER","populationDescription":"ADA analyses were based on ADA observations from participants who had received atezolizumab treatment and were evaluated for immunogenicity.","reportingStatus":"POSTED","timeFrame":"Predose (0 hours [H]) on Day (D) 1 of Cycles (C) 1, 2, 3, 4, 8, 16, and every 8 cycles (Q8C) thereafter (cycle = 21 days) until treatment discontinuation (up to 23 months) and 120 days after last dose (up to approximately 23 months overall)","title":"Percentage of Participants With Anti-Drug Antibodies (ADA) to Atezolizumab in the Global Population","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}